Novartis AG has heralded another strong quarter of sales growth for Entresto but is setting up its defences to keep the threat of generic competition at bay, while planning for further growth in the lucrative China market.
As Entresto Sales Soar, Novartis Braces For Generics Battle
Swiss Major Is Banking On China To Drive Growth
Novartis CEO Vas Narasimhan has told Scrip that the company is “aggressively defending each group of patents” on its cardiovascular blockbuster which topped the $900m sales mark in the fourth quarter.
More from Cardiovascular
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.